BioXcel Therapeutics Inc (BTAI) — Strategic Asset Allocation Index
BioXcel Therapeutics Inc (BTAI) has a Strategic Asset Allocation Index of 16.0% as of June 2023. Strategic assets (PP&E of $941.00K plus long-term investments of $-) total $941.00K, measured against net assets of $5.86 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See BTAI equity financing ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
BioXcel Therapeutics Inc Strategic Asset Allocation Index (2018–2022)
This chart shows how BioXcel Therapeutics Inc's Strategic Asset Allocation Index has evolved across 5 annual periods from 2018 to 2022. As of June 2023, the index stands at 16.0%, representing strategic assets of $941.00K against net assets of $5.86 Million USD. For live market cap and overall valuation, see BioXcel Therapeutics Inc stock valuation.
Annual Strategic Asset Allocation Index for BioXcel Therapeutics Inc (2018–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for BioXcel Therapeutics Inc from 2018 to 2022, covering 5 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See BioXcel Therapeutics Inc shareholders equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.4% | $1.08 Million | $1.08 Million | $- | $76.78 Million | ▲ +0.8 pp |
| 2021 | 0.6% | $1.29 Million | $1.29 Million | $- | $221.67 Million | ▼ 0.0 pp |
| 2020 | 0.6% | $1.27 Million | $1.27 Million | $- | $206.70 Million | ▼ -7.7 pp |
| 2019 | 8.3% | $2.23 Million | $2.23 Million | $- | $26.89 Million | ▲ +7.5 pp |
| 2018 | 0.8% | $327.00K | $327.00K | $- | $38.89 Million | — |